<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03698695</url>
  </required_header>
  <id_info>
    <org_study_id>THN201-101</org_study_id>
    <nct_id>NCT03698695</nct_id>
  </id_info>
  <brief_title>A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers</brief_title>
  <official_title>A Double Blind, Placebo-controlled, Randomized, 15-day Treatment, Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil Administered Orally to Healthy Male Volunteers Including a Scopolamine Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theranexus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theranexus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study explores the safety, pharmacodynamics and pharmacokinetics of THN201 a combination
      of donepezil and mefloquine to improve cognitive function in healthy male volunteers after
      impairment by a scopolamine challenge.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, 3-arm, parallel group study of 15 days duration including a
      scopolamine challenge at D15. Healthy male subjects will receive daily doses of THN201
      (donepezil 5 mg and mefloquine), donepezil 5 mg or placebo and one subcutaneous injection of
      scopolamine 0.5 mg on D15. Cognitive function, EEG and P300 will be assessed at baseline and
      before and after scopolamine challenge at D15. A final safety evaluation will be performed 2
      weeks after the end of the treatment period. Pharmacokinetic assessments will be performed to
      obtain a time/concentration profile of donepezil and mefloquine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 27, 2018</start_date>
  <completion_date type="Actual">December 20, 2019</completion_date>
  <primary_completion_date type="Actual">October 20, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamics: Cognitive function measured with the Cognitive Drug Research (CDR) test battery</measure>
    <time_frame>15 days</time_frame>
    <description>Main variable: Power of attention is the sum of the speed scores (msec) from three tests: Simple Reaction Time, Choice Reaction Time, and Digital Vigilance. Low values indicate better performance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Adverse events</measure>
    <time_frame>29 days</time_frame>
    <description>Number of subjects with spontaneously reported treatment related adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetics Plasma concentration of donepezil and mefloquine</measure>
    <time_frame>29 days</time_frame>
    <description>Time profile of plasma concentrations of donepezil and mefloquine</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamics measured by quantitative EEG (qEEG)</measure>
    <time_frame>15 days</time_frame>
    <description>Spectral analysis of absolute and/or relative amplitude in delta, theta, alpha, beta and gamma bands;</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamics measured by event related EEG potentials (P300)</measure>
    <time_frame>15 days</time_frame>
    <description>Auditory P300 parameters (amplitude, latency and AUC)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Cognitive Impairment</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>THN201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>THN201: Donepezil 5mg capsule and Mefloquine 10mg capsule once daily for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donepezil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Donepezil 5mg capsule and Mefloquine placebo capsule once daily for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Donepezil placebo capsule and Mefloquine placebo capsule once daily for 15 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THN 201</intervention_name>
    <description>THN 201: Donepezil 5 mg and Mefloquine 10 mg/d</description>
    <arm_group_label>THN201</arm_group_label>
    <other_name>Donepezil</other_name>
    <other_name>Mefloquine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>Donepezil 5 mg/d and Mefloquine placebo</description>
    <arm_group_label>Donepezil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Donepezil placebo and Mefloquine placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A body mass index (BMI), calculated as weight in kg/(height in m)², from 18 to 30
             kg/m², inclusive

          -  Healthy as determined by the investigator after a comprehensive clinical assessment
             based on medical history, physical examination, clinical laboratory test results,
             vital sign measurements, blood pressure (BP), heart rate (HR) and digital 12-lead ECG
             readings (all results should be normal or, if out of range, they should be
             non-clinically significant as determined by the investigator)

        Exclusion Criteria:

          -  Any significant cardiovascular (e.g. heart failure), pulmonary (including asthma),
             hepatic, renal, respiratory (e.g. asthma), gastrointestinal, endocrine (e.g. diabetes,
             dyslipidaemia), immunologic, dermatological, haematological, neurologic, psychiatric
             disease, history of any clinically important drug allergy, systemic or presence of
             infectious disease.

          -  Current suicide risk or history of suicide risk (C-SSRS baseline: &quot;yes&quot; answer to
             items 4 and/or 5).

          -  Brain imaging (MRI) at screening showing anatomical or vascular abnormality of any
             type.

          -  EEG examination at screening showing abnormal (epileptiform) activities.

          -  Symptomatic hypotension,

          -  Participants with, or with a history of cardiac arrhythmia or cardiac disease or a
             personal or family history of long QT syndrome or a family history of sudden death.

          -  Presence or history of drug hypersensitivity, or allergic disease diagnosed and
             treated by a physician.

          -  Antimalarial medicine intake or returning from a malaria-endemic area within the 12
             last months before the first IMP administration.

          -  Planning to visit a country requiring antimalarial chemoprophylaxis during the study
             period.

          -  History of adverse reaction after a previous mefloquine intake.

          -  Contraindication for the use of Aricept® or for one of its excipients.

          -  Contraindication for the use of piperidine derivative compounds or for other
             cholinesterase inhibitors.

          -  Contraindication for the use of Lariam® or for one of its excipients.

          -  Contraindication for the use of scopolamine S.C. injection.

          -  History or presence of drug or alcohol abuse (alcohol consumption &gt; 21 units / week).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Régis Bordet, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biotrial</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 2, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mefloquine</mesh_term>
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

